ID: ALA2179097

Max Phase: Preclinical

Molecular Formula: C15H21N5O2

Molecular Weight: 303.37

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@@H]1CNC[C@H]1c1nc2c(cnn2C2CCOCC2)c(=O)[nH]1

Standard InChI:  InChI=1S/C15H21N5O2/c1-9-6-16-7-11(9)13-18-14-12(15(21)19-13)8-17-20(14)10-2-4-22-5-3-10/h8-11,16H,2-7H2,1H3,(H,18,19,21)/t9-,11-/m1/s1

Standard InChI Key:  PYXRQSYDODFUOC-MWLCHTKSSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 303.37

Molecular Weight (Monoisotopic): 303.1695

AlogP: 0.79

#Rotatable Bonds: 2

Polar Surface Area: 84.83

Molecular Species: BASE

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.02

CX Basic pKa: 10.78

CX LogP: -1.58

CX LogD: -3.09

Aromatic Rings: 2

Heavy Atoms: 22

QED Weighted: 0.86

Np Likeness Score: -1.00

References

1. Verhoest PR, Fonseca KR, Hou X, Proulx-Lafrance C, Corman M, Helal CJ, Claffey MM, Tuttle JB, Coffman KJ, Liu S, Nelson F, Kleiman RJ, Menniti FS, Schmidt CJ, Vanase-Frawley M, Liras S..  (2012)  Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.,  55  (21): [PMID:22780914] [10.1021/jm3007799]

Source

Source(1):

• Scientific Literature